Organon's SWOT analysis: women's health leader faces biosimilar growth, LOE challenges
Organon & Co. (NYSE:OGN), a global healthcare company spun off from Merck (NSE:PROR) in 2021, has established itself as a leader in women's health while expanding its presence in biosimilars and ...
Investing4d
Organon's SWOT analysis: women's health leader faces biosimilar growth, LOE challenges
Want to discover more insights? InvestingPro subscribers have access to over 30 additional financial metrics and analysis tools. Nexplanon, a key product in the women's health portfolio, has been a ...